Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Seventh Tumor, Node, Metastasis Staging System and Lung Cancer Treatment Choices A Matter of Would, Could, and Should

The Seventh Tumor, Node, Metastasis Staging System and Lung Cancer Treatment Choices A Matter of... EDITORIAL The Seventh Tumor, Node, Metastasis Staging System and Lung Cancer Treatment Choices A Matter of Would, Could, and Should Johan F. Vansteenkiste, MD, PhD,* and Frances A. Shepherd, MD, PhD† he Seventh edition of the tumor, node, metastasis (TNM) classification of lung Tneoplasms (TNM7) has been in use since January 1, 2010. This is the result of the hitherto unprecedented work of the International Staging Committee of the International Association for the Study of Lung Cancer (IASLC) led by Mr. Peter Goldstraw. Based on more than 100,000 case records, changes to TNM6 were proposed and validated. The effort was rewarded by adoption of the new classification by both the American Joint Committee on Cancer and the Union Internationale Contre le Cancer and resulted in a 2 3 “seismic shift in lung cancer staging.” Most of the changes were in the T category ; the M1 category was adapted to M1a and M1b, whereas there were essentially no changes in the N categories. In this issue of Journal of Thoracic Oncology, Boffa et al. report on a study they performed to evaluate how much clinicians feel that a change in stage should lead to a change in management for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

The Seventh Tumor, Node, Metastasis Staging System and Lung Cancer Treatment Choices A Matter of Would, Could, and Should

Shepherd, Frances A.
Journal of Thoracic Oncology , Volume 5 (11) – Nov 1, 2010
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/the-seventh-tumor-node-metastasis-staging-system-and-lung-cancer-ZAcDGx0UFP

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3181f1906d
pmid
20975372
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL The Seventh Tumor, Node, Metastasis Staging System and Lung Cancer Treatment Choices A Matter of Would, Could, and Should Johan F. Vansteenkiste, MD, PhD,* and Frances A. Shepherd, MD, PhD† he Seventh edition of the tumor, node, metastasis (TNM) classification of lung Tneoplasms (TNM7) has been in use since January 1, 2010. This is the result of the hitherto unprecedented work of the International Staging Committee of the International Association for the Study of Lung Cancer (IASLC) led by Mr. Peter Goldstraw. Based on more than 100,000 case records, changes to TNM6 were proposed and validated. The effort was rewarded by adoption of the new classification by both the American Joint Committee on Cancer and the Union Internationale Contre le Cancer and resulted in a 2 3 “seismic shift in lung cancer staging.” Most of the changes were in the T category ; the M1 category was adapted to M1a and M1b, whereas there were essentially no changes in the N categories. In this issue of Journal of Thoracic Oncology, Boffa et al. report on a study they performed to evaluate how much clinicians feel that a change in stage should lead to a change in management for

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Nov 1, 2010

References

  • The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours
    Goldstraw
  • A seismic shift in staging
    Silvestri
  • The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer
    Rami-Porta
  • The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer
    Postmus
  • The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer
    Rusch
  • Should the 7th edition of the lung cancer stage classification system change treatment algorithms in NSCLC?
    Boffa
  • Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
    Pignon
  • Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer
    Winton
  • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
    Douillard
  • Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected non-small cell lung cancer (NSCLC): final results
    Vansteenkiste
  • Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
    Strauss
  • Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
    Besse
  • Surgical resection is justified in non-small cell lung cancer patients with node negative T4 satellite lesions
    Pennathur
  • Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer
    De Leyn